Providence Multiple Sclerosis Center is seeking people to take part in the following research studies:
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
This study is for patients with relapsing-remitting multiple sclerosis. Patients are randomly chosen (by chance) to receive laquinimod, 0.6 mg daily by mouth; placebo (inactive look-alike pill) or Avonex, 30 mcg weekly by injection. Laquinimod is an investigational medication not approved by the U.S. Food and Drug Administration (FDA). Patients must not have taken Copaxone in the previous two months and have never taken Avonex, Rebif, Betaseron or Tysabri.
All required study visits, tests and medications will be provided at no cost.
ENER-G Study: Evaluation of Natalizumab for the Relief of MS Associated Fatigue
This study is for patients with relapsing forms of multiple sclerosis who will start treatment with Tysabri. Patients must be newly enrolled to the TOUCH Tysabri Prescribing Program and have not yet received their first Tysabri infusion. Patients who join this study will be asked to complete one-hour neurological (having to do with the nerves or nervous system) tests on a computer eight different times.
All required study visits and tests will be provided at no cost.
CONFIRM Study: Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
This study is for patients with relapsing-remitting multiple sclerosis who cannot or will not take standard treatments. Patients are randomly assigned (by chance) to one of two different doses of an investigational medication (not approved by the FDA) called BG00012 that is taken by mouth, placebo (inactive look-alike capsules), or Copaxone, which is a standard MS medication taken as an injection under the skin. Patients must not have taken Avonex, Rebif, or Betaseron in the previous three months and cannot have taken Copaxone at any time.
All required study visits, tests and medications will be provided at no cost.
TOWER Study: An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis
This study is for patients with relapsing multiple sclerosis. Patients are randomly assigned (by chance) to one of two different doses of an investigational medication (not approved by the FDA) called Teriflunomide that is taken by mouth, or placebo (inactive look-alike capsule). Patients must not have had taken Copaxone, Avonex, Rebif or Betaseron in the previous three months, and cannot have taken Tysabri at any time.
All required study visits, tests and medications will be provided at no cost.
Atacicept in Optic Neuritis, Phase II This study is for patients diagnosed with unilateral symptomatic optic neuritis within the last 28 days. Patients will be randomly assigned (by chance) to receive an investigational drug called Atacicept or a placebo (inactive look-alike injection). Atacicept is not approved by the FDA. It is given as an injection under the skin every two weeks for the first four weeks and then weekly. Participation will last 48 weeks including follow up. Eligible patients must not have a prior history of optic neuritis, bilateral optic neuritis or multiple sclerosis.
All required study visits, tests and medications will be provided at no cost.
DRI10566: A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis
This study is for patients diagnosed with any type of MS who are experiencing walking disability. Patients are randomly assigned (by chance) to one of 3 different doses of an investigational medication (not approved by the FDA) called Nerispirdine that is taken by mouth, or placebo (inactive look-alike tablet). Patients must not have had a relapse in the past six months. Participation will last approximately 19 weeks total.
All required study visits, tests and medications will be provided at no cost.
For more information on these research studies, please contact the research coordinators, Tara De Graff, 503-216-2736, or Summer Carter, 503-216-1034.
Click here for more information on other clinical trials offered through Providence Brain Institute.
